Dimethyl fumarate: targeting glycolysis to treat MS

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2018,（6）
• 页码范围: 613-615
• 页数: 3页
• 语种: 英文

摘要

Dimethyl fumarate (DMF) is an immunomodulatory drug used in patients with multiple sclerosis (MS) and psoriasis.Kornberg and colleagues shed new light on DMF activity,demonstrating that it blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH),which confirms the pro-inflammatory role of glycolysis and points to potential new targets to treat inflammatory diseases such as MS.